Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-02921367
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravesical
01
Overview
PF-02921367 is an investigational permeation enhancer developed by Pfizer, specifically used as an intravesical pre-wash in the treatment of non-muscle invasive bladder cancer (NMIBC). Chemically identified as n-dodecyl-beta-D-maltoside (DDM), it is a surfactant designed to temporarily disrupt the glycosaminoglycan (GAG) layer and the tight junctions of the bladder urothelium. This action facilitates the uptake of subsequent therapeutic agents, such as the investigational drug PF-08052667, into the bladder wall. In clinical trials, it is typically administered as a 10-minute instillation immediately preceding the primary therapeutic dose.
- Other names
- n-dodecyl-beta-D-maltoside
Beyond the preview
Go deeper on PF-02921367.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-02921367.